Ionis Pharmaceuticals IONS Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| Collaborative Agreement Revenue | $465.79M+40.0% | $332.65M-5.7% | $352.66M+70.2% | $207.22M-55.7% | |
| Commercial | $435.85M+48.7% | $293.08M-5.0% | $308.59M+1.7% | $303.36M-11.4% | |
| Other Commercial | $35M-2.1% | $35.77M— | —— | $61.04M-18.2% | |
| Other Royalties | $24.16M+15.0% | $21.01M-35.2% | $32.42M— | —— | |
| Research And Development Revenue | $507.86M+23.2% | $412.06M-14.0% | $479.06M+68.7% | $284.01M-39.3% | |
| Royalty | $285.53M+11.0% | $257.31M-5.7% | $272.8M— | —— | |
| Spinraza Royalties | $212.28M-1.8% | $216.09M-10.1% | $240.38M-0.8% | $242.31M-9.5% | |
| Wainua Joint Development Revenue | $42.08M-47.0% | $79.42M-37.2% | $126.4M+64.6% | $76.79M— | |
| Wainus Royalties | $49.09M+143% | $20.21M— | $0— | $0— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Ionis Pharmaceuticals break its business down?
- Ionis Pharmaceuticals (IONS) reports revenue by product across 11 parts — Collaborative Agreement Revenue, Commercial, DAWNZERA Sales, Other Commercial and Other Royalties. Each is extracted from the segment footnotes and tracked over time.
- Where does Ionis Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Ionis Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
